trial

Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis

NCTId NCT04325568
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 25 (actual)
Sponsored by New York University
Primary completion 2022-07-31
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
25 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2020-11-16
Primary completion
2022-07-31
Eligibility
ALL · 16 Years · 30 Years

Interventions & indications

Drugs
PsyGist and Clinician Manual

Sponsors

New York UniversityLead Sponsor
New York State Psychiatric Institute, Washington Heights Community ServiceCollaborator

Investigators

1
Lawrence Yang, PhDPrincipal Investigator

Sites

1 total
New York, United States

Facts & assertions

4 sourced
Enrollment
25
Phase
PHASE1
Primary Completion Date
2022-07-31
Status
COMPLETED
relationships
The graph out of here
drug
PsyGist and Clinician Manual
drug
lead_sponsor
New York University
company
collaborator
New York State Psychiatric Institute, Washington Heights Community Service
company
indication
Psychosis
indication
Psychotic Disorders
indication
investigator
Lawrence Yang, PhD
person